Table: Towa Pharmaceutical - 9-MTH group results
Feb 13 (Reuters)-
Towa Pharmaceutical Co Ltd
CONSOLIDATED FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
9 months ended 9 months ended Year to
Dec 31, 2023 Dec 31, 2022 Mar 31, 2024
LATEST YEAR-AGO LATEST
RESULTS RESULTS FORECAST
Sales 168.33 140.41 229.00
(+19.9 pct) (+11.8 pct)
Operating 13.20 5.35 15.50
(+146.7 pct) (-68.5 pct)
Recurring 17.17 4.64 19.50
(+270.0 pct) (-78.0 pct)
Net 11.52 1.98 13.00
(+480.4 pct) (-86.8 pct)
EPS 234.03 yen 40.32 yen 264.12 yen
Ann Div 60.00 yen 60.00 yen
-Q2 div 30.00 yen 30.00 yen
-Q4 div 30.00 yen 30.00 yen
NOTE - Towa Pharmaceutical Co Ltd.
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4553.T
Recent news on TOWA PHARMACEUTICAL
See all newsTable: Towa Pharmaceutical -Q1 group results
Notice Of Acquisition Of Shares Of Tanabe Pharma Factory And Transfer Of Manufacturing And Marketing Approvals
Brief: Breckenridge Launches Tofacitinib Tablets, Generic Equivalent Of Xeljanz By Pfizer
Table: Towa Pharmaceutical -2025/26 parent results
Table: Towa Pharmaceutical -2025/26 group results